Institut fuer Klinische Transfusionsmedizin und Immungenetik Ulm gGmbH

Olilyw Eukdbdykn 4fg Emwfzzcpvi Ulzk 8xjwco Gorxias

Immune System Diseases

At Institut fuer Klinische Transfusionsmedizin und Immungenetik Ulm gGmbH, clinical research is centered on immune system diseases, with a strong focus on Paroxysmal Nocturnal Hemoglobinuria. The studies are designed to better understand this rare condition and to assess new treatment options that may improve long-term disease control and patient well-being.

Research on Paroxysmal Nocturnal Hemoglobinuria and related immune-mediated blood disorders
Evaluation of the safety and tolerability of new therapies for long-term use
Clinical work aimed at improving treatment effectiveness for patients with chronic immune system conditions

With 8 trials and 96 investigators involved, the site in Ulm contributes to advancing care for rare hematologic and immunologic diseases through focused clinical evaluation.

Evaluation of Safety, Pharmacokinetics, and Efficacy of RO7782493 and Panitumumab in Advanced Solid Tumors with KRAS G12D Mutation

Recruiting

2 1 1 1
Investigated Diseases:
- K-ras gene mutation
- Neoplasm
Investigated Drugs:
- Panitumumab
Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Recruiting

3 1 1
Investigated Diseases:
- Pancreatic carcinoma metastatic
Investigated Drugs:
+6
Durvalumab plus drug combination as total neoadjuvant therapy for patients with resectable gastroesophageal adenocarcinoma

Recruiting

2 1 1 1
Investigated Diseases:
- Oesophageal adenocarcinoma
Investigated Drugs:
Cevostamab plus pomalidomide and dexamethasone in patients with multiple myeloma previously treated with BCMA‑targeted CAR T‑cell therapy

Recruiting

2 1 1 1
Investigated Diseases:
- Plasma cell myeloma
Investigated Drugs:
Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Recruiting

3 1 1 1
Investigated Diseases:
- Pancreatic carcinoma metastatic
Investigated Drugs:
+5
Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease

Recruiting

3 1 1
Investigated Drugs:
- Golimumab
- Guselkumab
+9
Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

Recruiting

3 1 1
Investigated Drugs:
- Golimumab
- Guselkumab
+11
Study of RMC-6291 with ivonescimab drug combination in patients with advanced RAS‑mutated solid tumors

Recruiting

1 1 1 1
Investigated Drugs:
+3
A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

Recruiting

3 1

+16
Safety and Tolerability of Intrathecal TRCN-1023 in Adults with Amyotrophic Lateral Sclerosis (ALS) – Randomized Placebo‑Controlled Phase 1/2 Trial

Recruiting

1 1